Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM CLINICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Treatment after Asciminib

  • Kruti Patel
  • Kruti Patel's Avatar Topic Author
5 months 2 weeks ago - 5 months 2 days ago #1863 by Kruti Patel
Treatment after Asciminib was created by Kruti Patel
I was hoping to get some assistance about a complicated patient.

64Y AA with bilateral hearing loss, tinnitus. He was diagnosed with CML-CP 18 months ago and his baseline transcript level at was 43.1% and he was started on Dasatinib 50mg/day given tolerability concerns. His baseline BM showed grade 2 fibrosis and 7.5% blasts. At the 6.5 month, despite not reporting any missed doses, he lost his CHR and his ABL-PCR-b2a2 was 73%, (lowest was 16.25%). Repeat BM eval demonstrated showed ABL1 T315I, SUZ12 R121 and KMT2D R1219Q. No evidence of clonal evolution. He was started on ponatinib 45mg daily. Unfortunately, his transcript levels kept increasing to 74.35% without reaching hematologic remission, after being on therapy for 3 months. Due to concerning progression, he was started on Asciminib 200mg bid on 11/22/2021 and his transcript levels are unchanged at 3 months.

The patient has social barrier to getting an allo-transplant for several reason. Wanted to get advice on further management of this patient. Is there any evidence of adding any agent to Asciminib ? would you advice trying hydra and IFN?
Last edit: 5 months 2 days ago by arlene.
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
5 months 2 days ago - 5 months 2 days ago #1864 by Tim Hughes
Replied by Tim Hughes on topic Treatment after Asciminib
This unfortunate patient has proven to be refractory to dasatinib, ponatinib and now (very likely) asciminib. He had evidence of the T315I mutation emerging on dasatinib plus other non BCR::ABL1 mutations. This would be one of the rare occasions where an allograft is appropriate in the chronic phase but this is apparently not an option for him. At this stage I would:

1. Repeat the bone marrow aspirate with cytogenetics to see whether he has clonal evolution and whether he has progressed to AP or BC.
2. Repeat the mutation study – he may well have kinase domain (KD) mutations in addition to the T315I mutation.
3. Assess his level of haematological control on asciminib

If he has a dominant clone with compound mutations (T315I plus another KD mutation on the same BCR::ABL1 protein) no single TKI will be effective but there is evidence (Eide et al, Cancer cell 2019) that combined ponatinib and asciminib may be effective in this specific setting. This is probably an unrealistic approach due the cost however.

If asciminib is achieving haematological control, that may be the best response you will be able to achieve and would likely prolong survival when compared to just switching him to palliative therapy. If you are not even achieving haematological control then your options are extremely limited and your suggestion of hydroxyurea plus or minus interferon may well be a reasonable option.

I am interested to hear from other CML clinicians whether they have any other thoughts on this challenging case.
Last edit: 5 months 2 days ago by arlene.
Moderators: Melissa Davis-Bishop